Clinical evaluation of neoadjuvant tyrosine kinase inhibitor administration for mast cell tumours in eight dogs

Complete surgical removal of tumour cells is the first‐line treatment for canine cutaneous mast cell tumours. Surgical removal of mast cell tumours sometimes requires radical surgery. This may cause severe complications, loss of biological function or poor cosmetic outcomes. This report describes th...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary record case reports 2023-09, Vol.11 (3), p.n/a
Main Authors: Kanai, Eiichi, Sato, Asaka, Yamauchi, Akinori, Yoshida, Hiromitsu, Takagi, Satoshi
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c2541-ddbc2294abb70dc6f6b573af6c869d42c1453a4271b89f8c09610db2ffed974c3
container_end_page n/a
container_issue 3
container_start_page
container_title Veterinary record case reports
container_volume 11
creator Kanai, Eiichi
Sato, Asaka
Yamauchi, Akinori
Yoshida, Hiromitsu
Takagi, Satoshi
description Complete surgical removal of tumour cells is the first‐line treatment for canine cutaneous mast cell tumours. Surgical removal of mast cell tumours sometimes requires radical surgery. This may cause severe complications, loss of biological function or poor cosmetic outcomes. This report describes the clinical outcomes of preoperative administration of an effective tyrosine kinase inhibitor for mast cell tumours. Five of eight cases responded to tyrosine kinase inhibitors; complete removal was possible in three cases with narrower (
doi_str_mv 10.1002/vrc2.651
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2847923531</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2847923531</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2541-ddbc2294abb70dc6f6b573af6c869d42c1453a4271b89f8c09610db2ffed974c3</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMoWGrBnxDw4mVrMvt9lOIXCIKo15DNR5u6m9QkW-m_N2U9ePE0w_C8M--8CF1SsqSEwM3eC1hWJT1BMyAlZBUFevqnP0eLELaEEJo3TV7CDLlVb6wRvMdqz_uRR-Msdhpb5bjcjntuI44H74KxCn8ay4PCxm5MZ6LzmMshqUP0k06n0cBDxEL1PY7j4EYfEo6VWW8ilm4dLtCZ5n1Qi986R-_3d2-rx-z55eFpdfucCSgLmknZCYC24F1XEykqXXVlnXNdiaZqZQGCFmXOC6hp17S6EaStKJEdaK1kWxcin6Orae_Ou69Rhci2yYxNJxk0Rd1CXuY0UdcTJdKHwSvNdt4M3B8YJeyYKDsmylKiCc0m9Nv06vAvxz5eV3DkfwBz4Hlj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2847923531</pqid></control><display><type>article</type><title>Clinical evaluation of neoadjuvant tyrosine kinase inhibitor administration for mast cell tumours in eight dogs</title><source>Wiley</source><creator>Kanai, Eiichi ; Sato, Asaka ; Yamauchi, Akinori ; Yoshida, Hiromitsu ; Takagi, Satoshi</creator><creatorcontrib>Kanai, Eiichi ; Sato, Asaka ; Yamauchi, Akinori ; Yoshida, Hiromitsu ; Takagi, Satoshi</creatorcontrib><description>Complete surgical removal of tumour cells is the first‐line treatment for canine cutaneous mast cell tumours. Surgical removal of mast cell tumours sometimes requires radical surgery. This may cause severe complications, loss of biological function or poor cosmetic outcomes. This report describes the clinical outcomes of preoperative administration of an effective tyrosine kinase inhibitor for mast cell tumours. Five of eight cases responded to tyrosine kinase inhibitors; complete removal was possible in three cases with narrower (&lt;1 cm) surgical margins than the conventional tumour margin estimated from the original tumour size. Mast cell tumours may not require wide resection if they are responsive to tyrosine kinase inhibitors before surgical removal. Preoperative administration of tyrosine kinase inhibitors could be a treatment option for dogs that have difficulty with complete removal causing severe surgical complications, or for owners who do not accept loss of biological function or poor cosmetic outcomes.</description><identifier>ISSN: 2052-6121</identifier><identifier>EISSN: 2052-6121</identifier><identifier>DOI: 10.1002/vrc2.651</identifier><language>eng</language><publisher>London: Blackwell Publishing Ltd</publisher><ispartof>Veterinary record case reports, 2023-09, Vol.11 (3), p.n/a</ispartof><rights>2023 British Veterinary Association.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2541-ddbc2294abb70dc6f6b573af6c869d42c1453a4271b89f8c09610db2ffed974c3</cites><orcidid>0000-0002-9881-7283</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Kanai, Eiichi</creatorcontrib><creatorcontrib>Sato, Asaka</creatorcontrib><creatorcontrib>Yamauchi, Akinori</creatorcontrib><creatorcontrib>Yoshida, Hiromitsu</creatorcontrib><creatorcontrib>Takagi, Satoshi</creatorcontrib><title>Clinical evaluation of neoadjuvant tyrosine kinase inhibitor administration for mast cell tumours in eight dogs</title><title>Veterinary record case reports</title><description>Complete surgical removal of tumour cells is the first‐line treatment for canine cutaneous mast cell tumours. Surgical removal of mast cell tumours sometimes requires radical surgery. This may cause severe complications, loss of biological function or poor cosmetic outcomes. This report describes the clinical outcomes of preoperative administration of an effective tyrosine kinase inhibitor for mast cell tumours. Five of eight cases responded to tyrosine kinase inhibitors; complete removal was possible in three cases with narrower (&lt;1 cm) surgical margins than the conventional tumour margin estimated from the original tumour size. Mast cell tumours may not require wide resection if they are responsive to tyrosine kinase inhibitors before surgical removal. Preoperative administration of tyrosine kinase inhibitors could be a treatment option for dogs that have difficulty with complete removal causing severe surgical complications, or for owners who do not accept loss of biological function or poor cosmetic outcomes.</description><issn>2052-6121</issn><issn>2052-6121</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp1kE1LAzEQhoMoWGrBnxDw4mVrMvt9lOIXCIKo15DNR5u6m9QkW-m_N2U9ePE0w_C8M--8CF1SsqSEwM3eC1hWJT1BMyAlZBUFevqnP0eLELaEEJo3TV7CDLlVb6wRvMdqz_uRR-Msdhpb5bjcjntuI44H74KxCn8ay4PCxm5MZ6LzmMshqUP0k06n0cBDxEL1PY7j4EYfEo6VWW8ilm4dLtCZ5n1Qi986R-_3d2-rx-z55eFpdfucCSgLmknZCYC24F1XEykqXXVlnXNdiaZqZQGCFmXOC6hp17S6EaStKJEdaK1kWxcin6Orae_Ou69Rhci2yYxNJxk0Rd1CXuY0UdcTJdKHwSvNdt4M3B8YJeyYKDsmylKiCc0m9Nv06vAvxz5eV3DkfwBz4Hlj</recordid><startdate>202309</startdate><enddate>202309</enddate><creator>Kanai, Eiichi</creator><creator>Sato, Asaka</creator><creator>Yamauchi, Akinori</creator><creator>Yoshida, Hiromitsu</creator><creator>Takagi, Satoshi</creator><general>Blackwell Publishing Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0002-9881-7283</orcidid></search><sort><creationdate>202309</creationdate><title>Clinical evaluation of neoadjuvant tyrosine kinase inhibitor administration for mast cell tumours in eight dogs</title><author>Kanai, Eiichi ; Sato, Asaka ; Yamauchi, Akinori ; Yoshida, Hiromitsu ; Takagi, Satoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2541-ddbc2294abb70dc6f6b573af6c869d42c1453a4271b89f8c09610db2ffed974c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kanai, Eiichi</creatorcontrib><creatorcontrib>Sato, Asaka</creatorcontrib><creatorcontrib>Yamauchi, Akinori</creatorcontrib><creatorcontrib>Yoshida, Hiromitsu</creatorcontrib><creatorcontrib>Takagi, Satoshi</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Veterinary record case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kanai, Eiichi</au><au>Sato, Asaka</au><au>Yamauchi, Akinori</au><au>Yoshida, Hiromitsu</au><au>Takagi, Satoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical evaluation of neoadjuvant tyrosine kinase inhibitor administration for mast cell tumours in eight dogs</atitle><jtitle>Veterinary record case reports</jtitle><date>2023-09</date><risdate>2023</risdate><volume>11</volume><issue>3</issue><epage>n/a</epage><issn>2052-6121</issn><eissn>2052-6121</eissn><abstract>Complete surgical removal of tumour cells is the first‐line treatment for canine cutaneous mast cell tumours. Surgical removal of mast cell tumours sometimes requires radical surgery. This may cause severe complications, loss of biological function or poor cosmetic outcomes. This report describes the clinical outcomes of preoperative administration of an effective tyrosine kinase inhibitor for mast cell tumours. Five of eight cases responded to tyrosine kinase inhibitors; complete removal was possible in three cases with narrower (&lt;1 cm) surgical margins than the conventional tumour margin estimated from the original tumour size. Mast cell tumours may not require wide resection if they are responsive to tyrosine kinase inhibitors before surgical removal. Preoperative administration of tyrosine kinase inhibitors could be a treatment option for dogs that have difficulty with complete removal causing severe surgical complications, or for owners who do not accept loss of biological function or poor cosmetic outcomes.</abstract><cop>London</cop><pub>Blackwell Publishing Ltd</pub><doi>10.1002/vrc2.651</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-9881-7283</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 2052-6121
ispartof Veterinary record case reports, 2023-09, Vol.11 (3), p.n/a
issn 2052-6121
2052-6121
language eng
recordid cdi_proquest_journals_2847923531
source Wiley
title Clinical evaluation of neoadjuvant tyrosine kinase inhibitor administration for mast cell tumours in eight dogs
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T14%3A49%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20evaluation%20of%20neoadjuvant%20tyrosine%20kinase%20inhibitor%20administration%20for%20mast%20cell%20tumours%20in%20eight%20dogs&rft.jtitle=Veterinary%20record%20case%20reports&rft.au=Kanai,%20Eiichi&rft.date=2023-09&rft.volume=11&rft.issue=3&rft.epage=n/a&rft.issn=2052-6121&rft.eissn=2052-6121&rft_id=info:doi/10.1002/vrc2.651&rft_dat=%3Cproquest_cross%3E2847923531%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2541-ddbc2294abb70dc6f6b573af6c869d42c1453a4271b89f8c09610db2ffed974c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2847923531&rft_id=info:pmid/&rfr_iscdi=true